02.04
->
Search from website
Search from website
Our HybriFree Technology is based on B-cell cloning and used for efficient discovery of monoclonal antibodies from immunized chickens and rabbits, ready for their immediate production in mammalian cells. HybriFree antibody discovery is rapid, flexible and effective. It can also be used for cloning antibodies from recovered patients’ PBMCs or from existing hybridomas.
Total of 187 convalescent blood donors:
Criteria for antibody cloning:
Patient with high viral neutralization potency were selected for antibody cloning
Modelling with two 23G7 Fabs bound to the tri-S protein indicated sterical interference of the Fabs limiting the unbound RBD to move in the "up" ACE2 binding conformation
79C3 clone was identified as potent SARS-CoV-2 VoC neutralizing antibody. Humanization on 79C3 retained developability and functional neutralization profile.
We identified highly potent SARS-CoV-2 neutralizing antibodies that were active at low picomolar concentrations
ย
Formatting IgG into secretory IgA results in increased neutralization activity and resistance to independent mutations
ยฉ 2025 Icosagen
